Prostate-specific antigen velocity in untreated, localized prostate cancer

BJU International

Volumn 101, Issue 2, 2008, Pages 161-164

  Venkitaraman, Ramachandran ^a   Norman, Andrew ^b   Woode Amissah, Ruth ^a   Dearnaley, David ^a   Horwich, Alan ^a   Huddart, Robert ^a   Parker, Chris ^a,c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Active surveillance; Prostate cancer; PSA kinetics; Treatment choice

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER STAGING; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; KINETICS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT MONITORING; PATIENT SELECTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR BIOPSY;

ADULT; AGED; BIOPSY, NEEDLE; CHOICE BEHAVIOR; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 37349039305     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07175.x     Document Type: Article

References (22)

1. Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005 47 : 16 21
2. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004 5 : 101 6
3. Hardie C, Parker C, Norman A et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int 2005 95 : 956 60
4. Choo R, DeBoer G, Klotz L et al. PSA Doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001 50 : 615 20
5. Khan MA, Carter HB, Epstein JI et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 2003 170 : 2274 8
6. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004 171 : 1520 4
7. McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998 82 : 342 8
8. Fall K, Garmo H, Andren O et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007 99 : 526 32
9. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. Jama 2005 294 : 440 7
10. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004 351 : 125 35
11. Carter HB, Ferrucci L, Kettermann A et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006 98 : 1521 7
12. Terris MK, Klonecke AS, McDougall IR, Stamey TA. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 1991 32 : 1713 7
13. Do V, Choo R, De Boer G et al. The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. BJU Int 2002 89 : 703 9
14. Stephenson AJ, Aprikian AG, Souhami L et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002 59 : 652 6
15. Garzotto M, Beer TM, Hudson RG et al. Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol 2005 23 : 4322 9
16. Garzotto M, Park Y, Mongoue-Tchokote S et al. Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies. Cancer 2005 104 : 1911 7
17. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006 98 : 355 7
18. Kundu SD, Roehl KA, Yu X, Antenor JA, Suarez BK, Catalona WJ. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol 2007 177 : 505 9
19. Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol 2002 168 : 110 5
20. Freedland SJ, Kane CJ, Presti JC et al. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base. J Urol 2003 169 : 969 73
21. Brassell SA, Kao TC, Sun L, Moul JW. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology 2005 66 : 1229 33
22. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol 2003 170 : 370 2